DHR stock verdict - Avoid
DHR
DANAHER CORPORATION
AVOIDHealthcare
$224.49
Fundamentals below bar
$224.49
Heavy$102.58Buy$136.78Fair$170.97Exit$205.16
VALUE29
GROWTH19
QUALITY93
TECHNICAL—
TRUST SCORE
100High
confidence in this read — data completeness, earnings quality & coverage
Technicals: insufficient price history
PROS
- Conservative balance sheet — debt-to-equity of 0.48
- Converts 21% of revenue into free cash flow
- High gross margin of 59% (3-yr avg)
CONS
- Trades above the model's exit level ($205.16) — overvalued on this framework
- Expensive on trailing earnings (P/E 43.8×)
- Rich for its growth rate (PEG 4.4)
- Company has a low return on equity of 6.8% (TTM)
- Revenue declined 2.5%/yr on average over the last 3 years
✳ Pros and cons are machine-generated from the latest fundamentals and technicals.
EARNINGS QUALITY · we check the accounting so you don't have to
✓Operating cash flow is 178% of net income — profit is backed by real cash
Analysis as of 2026-09-25 · price live, fundamentals from latest filings
Congress Trading — last 90 days
See what senators are buying and selling on DHR. Sign in to unlock.
📊 Options Flow — Put/Call Ratio
FAQ
Why is DHR rated Avoid?
DHR (DANAHER CORPORATION) is rated Avoid because the model combines fundamentals, price action, and earnings-quality checks. The current signal is Fundamentals below bar. Conservative balance sheet — debt-to-equity of 0.48 and Converts 21% of revenue into free cash flow
Is DHR overvalued right now?
DHR is trading at $224.49 versus an estimated fair value of $170.97. That puts the stock in avoid territory on this framework. Trades above the model's exit level ($205.16) — overvalued on this framework and Expensive on trailing earnings (P/E 43.8×)
What should I watch before acting on DHR?
Watch the trust score of 100, the earnings-quality checks, and any red flags. Trades above the model's exit level ($205.16) — overvalued on this framework and Expensive on trailing earnings (P/E 43.8×)